Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We believe that these opportunities hold promise and represent an exciting aspect of our company's future |
| Equipment revenues remained strong versus historical levels because the majority of equipment sales are to variable key customers, we believe it is a sign of future potential growth in the fee per test market |
| I'm excited to announce continued growth in revenues and earnings in the fourth quarter 2023 |
| We continue to see strong demand from our home risk assessment customers using QuantaFlo for PAD during in-home examination |
| And as you saw in 2023, we did have record revenues for the year |
| This achievement is a testament to the hard work of our team as well as the ongoing support of our customers, who continue to recognize the clinical benefit and value of our technology |
| As I look into the future, I'm excited about Semler's potential to support the identification of chronic diseases by our customers, which is a large burden on our health care system |
| Year-over-year, we continue to achieve annual revenue and earnings growth |
| This proactive approach ensures that we continue providing our customers with a trusted solution, while positioning ourselves for future success in the broader cardiovascular diagnostic market |
| We believe the promising results that were published in two large independently conducted peer-reviewed study by QuantaFlo customers in 2022 are having an impact |
| As we set our sights on the future, we envision the health care landscape where our technology plays a pivotal role in shaping healthier outcomes for patients, while delivering substantial economic benefits to our customers |
| A key strength of our technology lies in its portability and accessibility, allowing us to actively contribute to addressing health and equity, prevalent and cardiovascular disease |
| Our long-term vision includes extending our reach to encompass additional cardiovascular applications, reflecting our dedication to continuous expansion |
| We extend our gratitude for your interest in our company and appreciate your continued support as we embark on this journey of innovation |
| The continued recognition of the value of this approach by our customers underscores the crucial role our technology plays for patients, physicians, facilities and payers in an evolving health care landscape |
| Our sales and marketing goals are, to further establish QuantaFlo for PAD as a standard of care given the proven clinical benefits of early diagnosis and preventative treatment and to diversify our customer base by adding medical centers, additional value-based care providers, penetrating deeper into the VA system and growing the self-insured employer, pharmaceutical and retail market |
| We believe that this proactive approach may save lives and also lower health care expenditures |
| We see continued interest in our products from the existing customers as well as new customers, such as hospitals, value-based care providers and major pharmaceutical and retailer markets |
| Moving forward, our primary objective remains setback to preserve and strengthen our current revenue opportunities and profitability within the chronic disease space with a focus on cardiovascular diseases |
| Variable fee revenues were $5.8 million, an increase of 28% year-over-year |
| Equipment and other revenue were $0.5 million, an increase of 71% year-over-year |
| Upon achieving this milestone, our focus will shift towards effectively upselling our existing customer base with this enhanced offering |
| Total revenues in Q4, 2023 were $15.1 million, an increase of 9% compared to the fourth quarter of 2022 |
| Good |
| So, we were able to take out these expenses and you should see that more clearly going forward as we won't have these one-time items |
| We appreciate your participation in today's discussion, and thank you for your ongoing support |
| I know you're in a unique position as you interact with the MA plan sponsors out there |
| Through strategic partnerships and exploring new opportunities, we aim to broaden our impact on the market and expand our offering |
| By supporting early diagnosis of peripheral arterial disease, we are hopeful that health care providers will initiate -- management of chronic cardiovascular disease |
| Brooks O'Neil Thank you very much |
| Statement |
|---|
| We saw end of 2023 cleanup of underutilized units by some customers, resulting in the decline |
| Fixed fee revenues were $8.8 million, a decrease of 2% year-over-year |
| You would say right this minute, you're not seeing much in the way of new interest from MA plan sponsors and there could be some softening of demand from existing customers in that arena |
| I'm just curious |
| While we've continued to market Insulin Insights, because we believe in its clinical benefit for diabetic patients, our marketing efforts over the past three years have not yielded significant results to date |
Please consider a small donation if you think this website provides you with relevant information